Announced
Completed
Synopsis
Investment company Shenzhen Investment Holdings led a $147m Series C round in Hinova Pharmaceuticals, a Chengdu-based drug research firm, with participation from Huarong Rongde Asset Management, Hangzhou Tigermed, and Sinopharm-CICC Capital. The financing capital will be used to support multi-center clinical trials and to commercialize the firm’s drug candidates locally and internationally.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.